This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Bellan DG, Filho RJ, Garcia JG, de Toledo Petrilli M, Maia Viola DC, Schoedl MF, Petrilli AS. Ewing's sarcoma: Epidemiology and prognosis for patients treated at the Pediatric Oncology Institute, IOP-GRAACC-UNIFESP. Rev Bras Ortop. 2015 Dec 8;47(4):446–450. doi:10.1016/S2255-4971(15)30126-9. PMID: 27047848; PMCID: PMC4799471.BellanDGFilhoRJGarciaJGde Toledo PetrilliMMaia ViolaDCSchoedlMFPetrilliASEwing's sarcoma: Epidemiology and prognosis for patients treated at the Pediatric Oncology Institute, IOP-GRAACC-UNIFESP2015Dec847444645010.1016/S2255-4971(15)30126-9PMID: 27047848; PMCID: PMC4799471.479947127047848Open DOISearch in Google Scholar
Franchi A. Epidemiology and classification of bone tumors. Clin Cases Miner Bone Metab. 2012 May;9(2):92–95. Epub 2012 Sep 30. PMID: 23087718; PMCID: PMC3476517.FranchiAEpidemiology and classification of bone tumors2012May929295Epub 2012 Sep 30. PMID: 23087718; PMCID: PMC3476517.Search in Google Scholar
Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, Juergens H. Ewing's sarcoma family of tumors: Current management. Oncologist. 2006 May;11(5):503–519. doi:10.1634/theoncologist.11-5-503. PMID: 16720851.BernsteinMKovarHPaulussenMRandallRLSchuckATeotLAJuergensHEwing's sarcoma family of tumors: Current management2006May11550351910.1634/theoncologist.11-5-503PMID: 16720851.16720851Open DOISearch in Google Scholar
Jedlicka P. Ewing sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol. 2010 Mar 19;3(4):338–347. PMID: 20490326; PMCID: PMC2872742.JedlickaPEwing sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions2010Mar1934338347PMID: 20490326; PMCID: PMC2872742.Search in Google Scholar
Miser JS, Goldsby RE, Chen Z, Krailo MD, Tarbell NJ, Link MP, et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: Evaluation of increasing the dose intensity of chemotherapy—A report from the Children's Oncology Group. Pediatr Blood Cancer. 2007 Dec;49(7):894–900. doi:10.1002/pbc.21233. PMID: 17584910.MiserJSGoldsbyREChenZKrailoMDTarbellNJLinkMPTreatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: Evaluation of increasing the dose intensity of chemotherapy—A report from the Children's Oncology Group2007Dec49789490010.1002/pbc.21233PMID: 17584910.17584910Open DOISearch in Google Scholar
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl. 4):iv79–iv95. doi:10.1093/annonc/mdy310. PMID: 30285218.CasaliPGBielackSAbecassisNAroHTBauerSBiaginiRESMO Guidelines Committee, PaedCan and ERN EURACANBone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up2018Oct129Suppl. 4iv79iv9510.1093/annonc/mdy310PMID: 30285218.30285218Open DOISearch in Google Scholar
Bacci G, Boriani S, Balladelli A, Barbieri E, Longhi A, Alberghini M, et al. Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: The experience from a single institution. Eur Spine J. 2009 Aug;18(8):1091–1095. doi:10.1007/s00586-009-0921-0. Epub 2009 Mar 11. PMID: 19277725; PMCID: PMC2899506.BacciGBorianiSBalladelliABarbieriELonghiAAlberghiniMTreatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: The experience from a single institution2009Aug1881091109510.1007/s00586-009-0921-0Epub 2009 Mar 11. PMID: 19277725; PMCID: PMC2899506.289950619277725Open DOISearch in Google Scholar
Serlo J, Helenius I, Vettenranta K, Perkkiö M, Riikonen P, Sampo M, Tarkkanen M. Surgically treated patients with axial and peripheral Ewing's sarcoma family of tumours: A population based study in Finland during 1990–2009. Eur J Surg Oncol. 2015 Jul;41(7):893–898. doi:10.1016/j.ejso.2015.02.010. Epub 2015 Mar 19. PMID: 25817983.SerloJHeleniusIVettenrantaKPerkkiöMRiikonenPSampoMTarkkanenMSurgically treated patients with axial and peripheral Ewing's sarcoma family of tumours: A population based study in Finland during 1990–20092015Jul41789389810.1016/j.ejso.2015.02.010Epub 2015 Mar 19. PMID: 25817983.25817983Open DOISearch in Google Scholar
Rodríguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, Daw NC, et al. Analysis of prognostic factors in Ewing sarcoma family of tumors: Review of St. Jude Children's Research Hospital studies. Cancer. 2007 Jul 15;110(2):375–384. doi:10.1002/cncr.22821. PMID: 17569105.Rodríguez-GalindoCLiuTKrasinMJWuJBillupsCADawNCAnalysis of prognostic factors in Ewing sarcoma family of tumors: Review of St. Jude Children's Research Hospital studies2007Jul15110237538410.1002/cncr.22821PMID: 17569105.17569105Open DOISearch in Google Scholar
Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors—A subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. 1994 Aug 4;331(5):294–299. doi:10.1056/NEJM199408043310503. PMID: 8022439.DelattreOZucmanJMelotTGarauXSZuckerJMLenoirGMThe Ewing family of tumors—A subgroup of small-round-cell tumors defined by specific chimeric transcripts1994Aug4331529429910.1056/NEJM199408043310503PMID: 8022439.8022439Open DOISearch in Google Scholar
Denny CT. Gene rearrangements in Ewing's sarcoma. Cancer Invest. 1996;14(1):83–88. doi:10.3109/07357909609018438. PMID: 8597892.DennyCTGene rearrangements in Ewing's sarcoma1996141838810.3109/07357909609018438PMID: 8597892.8597892Open DOISearch in Google Scholar
Li S, Siegal GP. Small cell tumors of bone. Adv Anat Pathol. 2010 Jan;17(1):1–11. doi:10.1097/PAP.0b013e3181bb6b9c. PMID: 20032633.LiSSiegalGPSmall cell tumors of bone2010Jan17111110.1097/PAP.0b013e3181bb6b9cPMID: 20032633.20032633Open DOISearch in Google Scholar
Ross KA, Smyth NA, Murawski CD, Kennedy JG. The biology of Ewing sarcoma. ISRN Oncol. 2013;2013:759725. doi:10.1155/2013/759725. Epub 2013 Jan 10. PMID: 23346417; PMCID: PMC3549336.RossKASmythNAMurawskiCDKennedyJGThe biology of Ewing sarcoma20132013759725.10.1155/2013/759725Epub 2013 Jan 10. PMID: 23346417; PMCID: PMC3549336.354933623346417Open DOISearch in Google Scholar
Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007 May;11(5):421–429. doi:10.1016/j.ccr.2007.02.027. PMID: 17482132.TirodeFLaud-DuvalKPrieurADelormeBCharbordPDelattreOMesenchymal stem cell features of Ewing tumors2007May11542142910.1016/j.ccr.2007.02.027PMID: 17482132.17482132Open DOISearch in Google Scholar
Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene. 2010 Aug 12;29(32):4504–4516. doi:10.1038/onc.2010.205. Epub 2010 Jun 14. PMID: 20543858; PMCID: PMC3555143.ToomeyECSchiffmanJDLessnickSLRecent advances in the molecular pathogenesis of Ewing's sarcoma2010Aug1229324504451610.1038/onc.2010.205Epub 2010 Jun 14. PMID: 20543858; PMCID: PMC3555143.355514320543858Open DOISearch in Google Scholar
Grünewald TG, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud MM, et al. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nat Genet. 2015 Sep;47(9):1073–1078. doi:10.1038/ng.3363. Epub 2015 Jul 27. PMID: 26214589; PMCID: PMC4591073.GrünewaldTGBernardVGilardi-HebenstreitPRaynalVSurdezDAynaudMMChimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite2015Sep4791073107810.1038/ng.3363Epub 2015 Jul 27. PMID: 26214589; PMCID: PMC4591073.459107326214589Open DOISearch in Google Scholar
J.A. Ludwig, N. Federman, P. Anderson, M.E. Macy, L.E. Davis, R.F. Riedel et al., Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma. Annals of Oncol. 2020;31(suppl_4):S914–S933. doi:10.1016/annonc/annonc288.LudwigJ.A.FedermanN.AndersonP.MacyM.E.DavisL.E.RiedelR.F.Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma202031suppl_4S914S93310.1016/annonc/annonc288Open DOISearch in Google Scholar
Cidre-Aranaz F, Alonso J. EWS/FLI1 Target genes and therapeutic opportunities in Ewing sarcoma. Front Oncol. 2015 Jul 20;5:162. doi:10.3389/fonc.2015.00162. PMID: 26258070; PMCID: PMC4507460.Cidre-AranazFAlonsoJEWS/FLI1 Target genes and therapeutic opportunities in Ewing sarcoma2015Jul20516210.3389/fonc.2015.00162PMID: 26258070; PMCID: PMC4507460.450746026258070Open DOISearch in Google Scholar
Dunst J, Jürgens H, Sauer R, Pape H, Paulussen M, Winkelmann W, Rübe C. Radiation therapy in Ewing's sarcoma: An update of the CESS 86 trial. Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):919–930. doi:10.1016/0360-3016(95)00016-r. PMID: 7607966.DunstJJürgensHSauerRPapeHPaulussenMWinkelmannWRübeCRadiation therapy in Ewing's sarcoma: An update of the CESS 86 trial1995Jul1532491993010.1016/0360-3016(95)00016-rPMID: 7607966.7607966Open DOISearch in Google Scholar
Schuck A, Ahrens S, Paulussen M, Kuhlen M, Könemann S, Rübe C, et al. Local therapy in localized Ewing tumors: Results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):168–177. doi:10.1016/s0360-3016(02)03797-5. PMID: 12504050.SchuckAAhrensSPaulussenMKuhlenMKönemannSRübeCLocal therapy in localized Ewing tumors: Results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials2003Jan155116817710.1016/s0360-3016(02)03797-5PMID: 12504050.12504050Open DOISearch in Google Scholar
Yock TI, Krailo M, Fryer CJ, Donaldson SS, Miser JS, Chen Z, et al. Children's Oncology Group. Local control in pelvic Ewing sarcoma: Analysis from INT-0091—A report from the Children's Oncology Group. J Clin Oncol. 2006 Aug 20;24(24):3838–3843. doi:10.1200/JCO.2006.05.9188. Erratum in: J Clin Oncol. 2006 Oct 20;24(30):4947. PMID: 16921035.YockTIKrailoMFryerCJDonaldsonSSMiserJSChenZChildren's Oncology GroupLocal control in pelvic Ewing sarcoma: Analysis from INT-0091—A report from the Children's Oncology Group2006Aug2024243838384310.1200/JCO.2006.05.9188Erratum in: J Clin Oncol. 2006 Oct 20;24(30):4947. PMID: 16921035.16921035Open DOISearch in Google Scholar
DuBois SG, Krailo MD, Gebhardt MC, Donaldson SS, Marcus KJ, Dormans J, et al. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children's Oncology Group. Cancer. 2015 Feb 1;121(3):467–475. doi:10.1002/cncr.29065. Epub 2014 Sep 23. PMID: 25251206; PMCID: PMC4305012.DuBoisSGKrailoMDGebhardtMCDonaldsonSSMarcusKJDormansJComparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children's Oncology Group2015Feb1121346747510.1002/cncr.29065Epub 2014 Sep 23. PMID: 25251206; PMCID: PMC4305012.430501225251206Open DOISearch in Google Scholar
Schuck A, Ahrens S, von Schorlemer I, Kuhlen M, Paulussen M, Hunold A, et al. Radiotherapy in Ewing tumors of the vertebrae: Treatment results and local relapse analysis of the CESS 81/86 and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1562–1567. doi:10.1016/j.ijrobp.2005.05.036. Epub 2005 Aug 30. PMID: 16137838.SchuckAAhrensSvon SchorlemerIKuhlenMPaulussenMHunoldARadiotherapy in Ewing tumors of the vertebrae: Treatment results and local relapse analysis of the CESS 81/86 and EICESS 92 trials2005Dec16351562156710.1016/j.ijrobp.2005.05.036Epub 2005 Aug 30. PMID: 16137838.16137838Open DOISearch in Google Scholar
Indelicato DJ, Keole SR, Shahlaee AH, Shi W, Morris CG, Marcus RB Jr. Definitive radiotherapy for Ewing tumors of extremities and pelvis: Long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):871–877. doi:10.1016/j.ijrobp.2008.02.023. Epub 2008 May 1. PMID: 18455323.IndelicatoDJKeoleSRShahlaeeAHShiWMorrisCGMarcusRBJrDefinitive radiotherapy for Ewing tumors of extremities and pelvis: Long-term disease control, limb function, and treatment toxicity2008Nov172387187710.1016/j.ijrobp.2008.02.023Epub 2008 May 1. PMID: 18455323.18455323Open DOISearch in Google Scholar
Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study. J Clin Oncol. 1990 Oct;8(10):1664–1674. doi:10.1200/JCO.1990.8.10.1664. PMID: 2213103.NesbitMEJrGehanEABurgertEOJrViettiTJCangirATefftMMultimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study1990Oct8101664167410.1200/JCO.1990.8.10.1664PMID: 2213103.2213103Open DOISearch in Google Scholar
Burgert EO Jr, Nesbit ME, Garnsey LA, Gehan EA, Herrmann J, Vietti TJ, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol. 1990 Sep;8(9):1514–1524. doi:10.1200/JCO.1990.8.9.1514. PMID: 2099751.BurgertEOJrNesbitMEGarnseyLAGehanEAHerrmannJViettiTJMultimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II1990Sep891514152410.1200/JCO.1990.8.9.1514PMID: 2099751.2099751Open DOISearch in Google Scholar
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003 Feb 20;348(8):694–701. doi:10.1056/NEJMoa020890. PMID: 12594313.GrierHEKrailoMDTarbellNJLinkMPFryerCJPritchardDJAddition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone2003Feb20348869470110.1056/NEJMoa020890PMID: 12594313.12594313Open DOISearch in Google Scholar
Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A Children's Oncology Group Study. J Clin Oncol. 2009 May 20;27(15):2536–2541. doi:10.1200/JCO.2008.19.1478. Epub 2009 Apr 6. PMID: 19349548; PMCID: PMC2684856.GranowetterLWomerRDevidasMKrailoMWangCBernsteinMDose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A Children's Oncology Group Study2009May2027152536254110.1200/JCO.2008.19.1478Epub 2009 Apr 6. PMID: 19349548; PMCID: PMC2684856.268485619349548Open DOISearch in Google Scholar
Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol. 2012 Nov 20;30(33):4148–4154. doi:10.1200/JCO.2011.41.5703. Epub 2012 Oct 22. Erratum in: J Clin Oncol. 2015 Mar 1;33(7):814. Dosage error in article text. PMID: 23091096; PMCID: PMC3494838.WomerRBWestDCKrailoMDDickmanPSPawelBRGrierHERandomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children's Oncology Group2012Nov2030334148415410.1200/JCO.2011.41.5703Epub 2012 Oct 22. Erratum in: J Clin Oncol. 2015 Mar 1;33(7):814. Dosage error in article text. PMID: 23091096; PMCID: PMC3494838.349483823091096Open DOISearch in Google Scholar
Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, et al. European Intergroup Cooperative Ewing's Sarcoma Study-92. Results of the EICESS-92 Study: Two randomized trials of Ewing's sarcoma treatment—Cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008 Sep 20;26(27):4385–4393. doi:10.1200/JCO.2008.16.5720. PMID: 18802150.PaulussenMCraftAWLewisIHackshawADouglasCDunstJEuropean Intergroup Cooperative Ewing's Sarcoma Study-92. Results of the EICESS-92 Study: Two randomized trials of Ewing's sarcoma treatment—Cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients2008Sep2026274385439310.1200/JCO.2008.16.5720PMID: 18802150.18802150Open DOISearch in Google Scholar
Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: Results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol. 2014 Aug 10;32(23):2440–2448. doi:10.1200/JCO.2013.54.4833. Epub 2014 Jun 30. PMID: 24982464.Le DeleyMCPaulussenMLewisIBrennanBRanftAWhelanJCyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: Results of the randomized noninferiority Euro-EWING99-R1 trial2014Aug1032232440244810.1200/JCO.2013.54.4833Epub 2014 Jun 30. PMID: 24982464.24982464Open DOISearch in Google Scholar
Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, et al. Euro-E.W.I.N.G.99 and EWING-2008 Investigators. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018 Sep 6;36(31):JCO2018782516. doi:10.1200/JCO.2018.78.2516. Epub ahead of print. PMID: 30188789; PMCID: PMC6209090.WhelanJLe DeleyMCDirksenULe TeuffGBrennanBGasparNEuro-E.W.I.N.G.99 and EWING-2008 Investigators. High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-20082018Sep63631JCO2018782516.10.1200/JCO.2018.78.2516Epub ahead of print. PMID: 30188789; PMCID: PMC6209090.620909030188789Open DOISearch in Google Scholar
Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL, et al. Long-term survivors of childhood Ewing sarcoma: Report from the childhood cancer survivor study. J Natl Cancer Inst. 2010 Aug 18;102(16):1272–1283. doi:10.1093/jnci/djq278. Epub 2010 Jul 23. PMID: 20656964; PMCID: PMC2948841.GinsbergJPGoodmanPLeisenringWNessKKMeyersPAWoldenSLLong-term survivors of childhood Ewing sarcoma: Report from the childhood cancer survivor study2010Aug18102161272128310.1093/jnci/djq278Epub 2010 Jul 23. PMID: 20656964; PMCID: PMC2948841.294884120656964Open DOISearch in Google Scholar
Eiser C. Assessment of health-related quality of life after bone cancer in young people: Easier said than done. Eur J Cancer. 2009 Jul;45(10):1744–1747. doi:10.1016/j.ejca.2009.02.025. Epub 2009 Mar 25. PMID: 19327986.EiserCAssessment of health-related quality of life after bone cancer in young people: Easier said than done2009Jul45101744174710.1016/j.ejca.2009.02.025Epub 2009 Mar 25. PMID: 19327986.19327986Open DOISearch in Google Scholar
Hobusch GM, Lang N, Schuh R, Windhager R, Hofstaetter JG. Do patients with Ewing's sarcoma continue with sports activities after limb salvage surgery of the lower extremity? Clin Orthop Relat Res. 2015 Mar;473(3):839–846. doi:10.1007/s11999-014-3622-x. PMID: 24748070; PMCID: PMC4317429.HobuschGMLangNSchuhRWindhagerRHofstaetterJGDo patients with Ewing's sarcoma continue with sports activities after limb salvage surgery of the lower extremity?2015Mar473383984610.1007/s11999-014-3622-xPMID: 24748070; PMCID: PMC4317429.431742924748070Open DOISearch in Google Scholar
Groundland JS, Ambler SB, Houskamp LD, Orriola JJ, Binitie OT, Letson GD. Surgical and functional outcomes after limb-preservation surgery for tumor in pediatric patients: A systematic review. JBJS Rev. 2016 Feb9;4(2):01874474-201602000-00002. doi:10.2106/JBJS.RVW.O.00013. PMID: 27490132.GroundlandJSAmblerSBHouskampLDOrriolaJJBinitieOTLetsonGDSurgical and functional outcomes after limb-preservation surgery for tumor in pediatric patients: A systematic review2016Feb94201874474-201602000-00002.10.2106/JBJS.RVW.O.00013PMID: 27490132.27490132Open DOISearch in Google Scholar
Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, Pentheroudakis G, ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(Suppl 6):vi160–170. doi:10.1093/annonc/mdt199. Epub 2013 Jun 27. PMID: 23813932.PeccatoriFAAzimHAJrOrecchiaRHoekstraHJPavlidisNKesicVPentheroudakisGESMO Guidelines Working GroupCancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up2013Oct24Suppl 6vi16017010.1093/annonc/mdt199Epub 2013 Jun 27. PMID: 23813932.23813932Open DOISearch in Google Scholar
Romao RL, Lorenzo AJ. Fertility preservation options for children and adolescents with cancer. Can Urol Assoc J. 2017 Jan–Feb;11(1–2, Suppl 1):S97–S102. doi:10.5489/cuaj.4410. PMID: 28265333; PMCID: PMC5332250.RomaoRLLorenzoAJFertility preservation options for children and adolescents with cancer2017Jan–Feb111–2, Suppl 1S97S10210.5489/cuaj.4410PMID: 28265333; PMCID: PMC5332250.533225028265333Open DOISearch in Google Scholar
Chen H, Xiao L, Li J, Cui L, Huang W. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2019 Mar 3;3(3):CD008018. doi:10.1002/14651858.CD008018.pub3. PMID: 30827035; PMCID: PMC6397718.ChenHXiaoLLiJCuiLHuangWAdjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women2019Mar333CD008018.10.1002/14651858.CD008018.pub3PMID: 30827035; PMCID: PMC6397718.639771830827035Open DOISearch in Google Scholar
Kyriazoglou A, Tsironis G, Liontos M, Papakosta A, Mahaira L, Thomakos N, et al., Ewing's sarcoma of the cervix: A case report of an unusual diagnosis in pregnancy treated with surgery, adjuvant VIDE and radiotherapy. Oncol Lett. 2019 Jun;17(6):5529–5535. doi:10.3892/ol.2019.10267. Epub 2019 Apr 18. PMID: 31186774; PMCID: PMC6507342.KyriazoglouATsironisGLiontosMPapakostaAMahairaLThomakosNEwing's sarcoma of the cervix: A case report of an unusual diagnosis in pregnancy treated with surgery, adjuvant VIDE and radiotherapy2019Jun1765529553510.3892/ol.2019.10267Epub 2019 Apr 18. PMID: 31186774; PMCID: PMC6507342.650734231186774Open DOISearch in Google Scholar
Rodriguez-Galindo C, Billups CA, Kun LE, Rao BN, et al. Survival after recurrence of Ewing tumors: The St Jude Children's Research Hospital experience, 1979–1999. Cancer. 2002 Jan 15;94(2):561–569. doi:10.1002/cncr.10192. PMID: 11900241.Rodriguez-GalindoCBillupsCAKunLERaoBNSurvival after recurrence of Ewing tumors: The St Jude Children's Research Hospital experience, 1979–19992002Jan1594256156910.1002/cncr.10192PMID: 11900241.11900241Open DOISearch in Google Scholar
Bacci G, Ferrari S, Longhi A, Donati D, De Paolis M, Forni C, et al. Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol. 2003 Nov;14(11):1654–1659. doi:10.1093/annonc/mdg457. PMID: 14581274.BacciGFerrariSLonghiADonatiDDe PaolisMForniCTherapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 19972003Nov14111654165910.1093/annonc/mdg457PMID: 14581274.14581274Open DOISearch in Google Scholar
Robinson SI, Ahmed SK, Okuno SH, Arndt CA, Rose PS, Laack NN. Clinical outcomes of adult patients with relapsed Ewing sarcoma: A 30-year single-institution experience. Am J Clin Oncol. 2014 Dec;37(6):585–591. doi:10.1097/COC.0b013e318281d6ab. PMID: 23466580.RobinsonSIAhmedSKOkunoSHArndtCARosePSLaackNNClinical outcomes of adult patients with relapsed Ewing sarcoma: A 30-year single-institution experience2014Dec37658559110.1097/COC.0b013e318281d6abPMID: 23466580.23466580Open DOISearch in Google Scholar
Navid F, Billups C, Liu T, Krasin MJ, Rodriguez-Galindo C. Second cancers in patients with the Ewing sarcoma family of tumours. Eur J Cancer. 2008 May;44(7):983–991. doi:10.1016/j.ejca.2008.02.027. Epub 2008 Mar 18. PMID: 18353632; PMCID: PMC2423466.NavidFBillupsCLiuTKrasinMJRodriguez-GalindoCSecond cancers in patients with the Ewing sarcoma family of tumours2008May44798399110.1016/j.ejca.2008.02.027Epub 2008 Mar 18. PMID: 18353632; PMCID: PMC2423466.242346618353632Open DOISearch in Google Scholar
Rodriguez-Galindo C, Poquette CA, Marina NM, Head DR, Cain A, et al. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol Oncol. 2000 Jul–Aug;22(4):321–329. doi:10.1097/00043426-200007000-00008. PMID: 10959902.Rodriguez-GalindoCPoquetteCAMarinaNMHeadDRCainAHematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors2000Jul–Aug22432132910.1097/00043426-200007000-00008PMID: 10959902.10959902Open DOISearch in Google Scholar
Anderson P, Kopp L, Anderson N, Cornelius K, Herzog C, Hughes D, Huh W. Novel bone cancer drugs: Investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investig Drugs. 2008 Nov;17(11):1703–1715. doi:10.1517/13543784.17.11.1703. PMID: 18922107.AndersonPKoppLAndersonNCorneliusKHerzogCHughesDHuhWNovel bone cancer drugs: Investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma)2008Nov17111703171510.1517/13543784.17.11.1703PMID: 18922107.18922107Open DOISearch in Google Scholar
Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, Albritton K. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007 Feb;48(2):132–139. doi:10.1002/pbc.20697. PMID: 16317751.WagnerLMMcAllisterNGoldsbyRERausenARMcNall-KnappRYMcCarvilleMBAlbrittonKTemozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma2007Feb48213213910.1002/pbc.20697PMID: 16317751.16317751Open DOISearch in Google Scholar
Raciborska A, Bilska K, Drabko K, Chaber R, Pogorzala M, Wyrobek E, et al. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 2013 Oct;60(10):1621–1625. doi:10.1002/pbc.24621. Epub 2013 Jun 15. PMID: 23776128.RaciborskaABilskaKDrabkoKChaberRPogorzalaMWyrobekEVincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma2013Oct60101621162510.1002/pbc.24621Epub 2013 Jun 15. PMID: 23776128.23776128Open DOISearch in Google Scholar
Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, Meyers PA. Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2009 Dec;53(6):1029–1034. doi:10.1002/pbc.22206. PMID: 19637327.CaseyDAWexlerLHMerchantMSChouAJMerolaPRPriceAPMeyersPAIrinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience2009Dec5361029103410.1002/pbc.22206PMID: 19637327.19637327Open DOISearch in Google Scholar
Palmerini E, Jones RL, Setola E, Picci P, Marchesi E, Luksch R, et al. Irinotecan and temozolomide in recurrent Ewing sarcoma: An analysis in 51 adult and pediatric patients. Acta Oncol. 2018 Jul;57(7):958–964. doi:10.1080/0284186X.2018.1449250. Epub 2018 Mar 13. PMID: 29533113.PalmeriniEJonesRLSetolaEPicciPMarchesiELukschRIrinotecan and temozolomide in recurrent Ewing sarcoma: An analysis in 51 adult and pediatric patients2018Jul57795896410.1080/0284186X.2018.1449250Epub 2018 Mar 13. PMID: 29533113.29533113Open DOISearch in Google Scholar
Büyükkapu Bay S, Kebudi R, Görgün O, Zülfikar B, Darendeliler E, Çakır FB. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience. J Oncol Pharm Pract. 2019 Sep;25(6):1343–1348. doi:10.1177/1078155218790798. Epub 2018 Aug 6. PMID: 30080131.Büyükkapu BaySKebudiRGörgünOZülfikarBDarendelilerEÇakırFBVincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience2019Sep2561343134810.1177/1078155218790798Epub 2018 Aug 6. PMID: 30080131.30080131Open DOISearch in Google Scholar
Kurucu N, Sari N, Ilhan IE. Irinotecan and temozolamide treatment for relapsed Ewing sarcoma: A single-center experience and review of the literature. Pediatr Hematol Oncol. 2015 Feb;32(1):50–59. doi:10.3109/08880018.2014.954070. Epub 2014 Sep 24. PMID: 25252096.KurucuNSariNIlhanIEIrinotecan and temozolamide treatment for relapsed Ewing sarcoma: A single-center experience and review of the literature2015Feb321505910.3109/08880018.2014.954070Epub 2014 Sep 24. PMID: 25252096.25252096Open DOISearch in Google Scholar
Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538–545. doi:10.1002/pbc.22407. PMID: 20049936; PMCID: PMC3074342.WagnerLMPerentesisJPReidJMAmesMMSafgrenSLNelsonMDJrIngleAMBlaneySMAdamsonPCPhase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study2010Apr54453854510.1002/pbc.22407PMID: 20049936; PMCID: PMC3074342.307434220049936Open DOISearch in Google Scholar
Wagner LM. Fifteen years of irinotecan therapy for pediatric sarcoma: Where to next? Clin Sarcoma Res. 2015 Aug 28;5:20. doi:10.1186/s13569-015-0035-x. PMID: 26322224; PMCID: PMC4552408.WagnerLMFifteen years of irinotecan therapy for pediatric sarcoma: Where to next?2015Aug2852010.1186/s13569-015-0035-xPMID: 26322224; PMCID: PMC4552408.455240826322224Open DOISearch in Google Scholar
Wagner LM, Crews KR, Iacono LC, Houghton PJ, Fuller CE, McCarville MB, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res. 2004 Feb 1;10(3):840–848. doi:10.1158/1078-0432.ccr-03-0175. PMID: 14871959.WagnerLMCrewsKRIaconoLCHoughtonPJFullerCEMcCarvilleMBPhase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors2004Feb110384084810.1158/1078-0432.ccr-03-0175PMID: 14871959.14871959Open DOISearch in Google Scholar
Rapkin L, Qayed M, Brill P, Martin M, Clark D, George BA, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer. 2012 Nov;59(5):854–58. doi:10.1002/pbc.24101. Epub 2012 Feb 2. PMID: 22302783.RapkinLQayedMBrillPMartinMClarkDGeorgeBAGemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas2012Nov5958545810.1002/pbc.24101Epub 2012 Feb 2. PMID: 22302783.22302783Open DOISearch in Google Scholar
Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008 Jul 15;113(2):419–425. doi:10.1002/cncr.23586. PMID: 18484657.NavidFWillertJRMcCarvilleMBFurmanWWatkinsARobertsWDawNCCombination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma2008Jul15113241942510.1002/cncr.23586PMID: 18484657.18484657Open DOISearch in Google Scholar
Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol. 2009 Oct;31(10):723–729. doi:10.1097/MPH.0b013e3181b2598c. PMID: 19727011.MoraJCruzCOPararedaAde TorresCTreatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel2009Oct311072372910.1097/MPH.0b013e3181b2598cPMID: 19727011.19727011Open DOISearch in Google Scholar
Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005 Apr;44(4):338–347. doi:10.1002/pbc.20227. PMID: 15503297.Van WinklePAngiolilloAKrailoMCheungYKAndersonBDavenportVIfosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experience2005Apr44433834710.1002/pbc.20227PMID: 15503297.15503297Open DOISearch in Google Scholar
Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, et al. Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987 Aug;5(8):1191–1198. doi:10.1200/JCO.1987.5.8.1191. PMID: 3114435.MiserJSKinsellaTJTricheTJTsokosMJarosinskiPForquerRIfosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults1987Aug581191119810.1200/JCO.1987.5.8.1191PMID: 3114435.3114435Open DOISearch in Google Scholar
Nardo M, Zambrano EM, Vicentini MF, Toloi D, Camargo VP, Feher O, Munhoz R. 5294—Efficacy of second line treatment with etoposide and ifosfamide in adult patients with advanced Ewing sarcoma family tumors. Annals of Oncol. 2017;28 (Suppl_5):v521–v538. doi:10.1093/annonc/mdx387.NardoMZambranoEMVicentiniMFToloiDCamargoVPFeherOMunhozR5294—Efficacy of second line treatment with etoposide and ifosfamide in adult patients with advanced Ewing sarcoma family tumors201728Suppl_5v521v53810.1093/annonc/mdx387Open DOISearch in Google Scholar
Kung FH, Pratt CB, Vega RA, Jaffe N, Strother D, Schwenn M, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer. 1993 Mar 1;71(5):1898–1903. doi:10.1002/1097-0142(19930301)71:5<1898::aidcncr2820710529>3.0.co;2-q. PMID: 8448755.KungFHPrattCBVegaRAJaffeNStrotherDSchwennMIfosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study1993Mar17151898190310.1002/1097-0142(19930301)71:5<1898::aidcncr2820710529>3.0.co;2-qPMID: 8448755.Open DOISearch in Google Scholar
Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer. 2006 Nov;47(6):795–800. doi:10.1002/pbc.20719. PMID: 16411206.HunoldAWeddelingNPaulussenMRanftALiebscherCJürgensHTopotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors2006Nov47679580010.1002/pbc.20719PMID: 16411206.16411206Open DOISearch in Google Scholar
Saylors RL III, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al., Pediatric Oncology Group. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol. 2001 Aug 1;19(15):3463–3469. doi:10.1200/JCO.2001.19.15.3463. PMID: 11481351.SaylorsRLIIIStineKCSullivanJKepnerJLWallDABernsteinMLPediatric Oncology GroupCyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study2001Aug119153463346910.1200/JCO.2001.19.15.3463PMID: 11481351.11481351Open DOISearch in Google Scholar
Farhat R, Raad R, Khoury NJ, Feghaly J, Eid T, Muwakkit S, et al. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed Ewing sarcoma at a single institution. J Pediatr Hematol Oncol. 2013 Jul;35(5):356–360. doi:10.1097/MPH.0b013e318270a343. PMID: 23042020.FarhatRRaadRKhouryNJFeghalyJEidTMuwakkitSCyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed Ewing sarcoma at a single institution2013Jul35535636010.1097/MPH.0b013e318270a343PMID: 23042020.23042020Open DOISearch in Google Scholar
Bernstein ML, Devidas M, Lafreniere D, Souid AK, Meyers PA, Gebhardt M, et al. Pediatric Oncology Group; Children's Cancer Group Phase II Study 9457; Children's Oncology Group. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457—A report from the Children's Oncology Group. J Clin Oncol. 2006 Jan 1;24(1):152–159. doi:10.1200/JCO.2005.02.1717. PMID: 16382125.BernsteinMLDevidasMLafreniereDSouidAKMeyersPAGebhardtMPediatric Oncology GroupChildren's Cancer Group Phase II Study 9457Children's Oncology GroupIntensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457—A report from the Children's Oncology Group2006Jan124115215910.1200/JCO.2005.02.1717PMID: 16382125.16382125Open DOISearch in Google Scholar
Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive Ewing sarcoma family tumors. Pediatr Hematol Oncol. 2013 Apr;30(3):170–77. doi:10.3109/08880018.2013.767868. PMID: 23484903.KebudiRCakirFBGorgunOAgaogluFYDarendelilerEA modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive Ewing sarcoma family tumors2013Apr3031707710.3109/08880018.2013.767868PMID: 23484903.23484903Open DOISearch in Google Scholar
Magnan H, Goodbody CM, Riedel E, Pratilas CA, Wexler LH, Chou AJ. Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. Pediatr Blood Cancer. 2015 Apr;62(4):594–597. doi:10.1002/pbc.25373. Epub 2015 Jan 28. PMID: 25630954; PMCID: PMC4474186.MagnanHGoodbodyCMRiedelEPratilasCAWexlerLHChouAJIfosfamide dose-intensification for patients with metastatic Ewing sarcoma2015Apr62459459710.1002/pbc.25373Epub 2015 Jan 28. PMID: 25630954; PMCID: PMC4474186.447418625630954Open DOISearch in Google Scholar
Ferrari S, del Prever AB, Palmerini E, Staals E, Berta M, Balladelli A, et al. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer. 2009 May;52(5):581–584. doi:10.1002/pbc.21917. PMID: 19142994.FerrariSdel PreverABPalmeriniEStaalsEBertaMBalladelliAResponse to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma2009May52558158410.1002/pbc.21917PMID: 19142994.19142994Open DOISearch in Google Scholar
Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies—Dose-response and schedule dependence. J Clin Oncol. 1997 Jun;15(6):2378–2384. doi:10.1200/JCO.1997.15.6.2378. PMID: 9196153.PatelSRVadhan-RajSPapadopolousNPlagerCBurgessMAHaysCBenjaminRSHigh-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies—Dose-response and schedule dependence1997Jun1562378238410.1200/JCO.1997.15.6.2378PMID: 9196153.9196153Open DOISearch in Google Scholar
McCabe MG, Moroz V, Khan M, Dirksen U, Evans A, Fenwick N, et al., Euro Ewing Consortium. Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. J Clin Oncol. 2019 37(15_suppl):11007.McCabeMGMorozVKhanMDirksenUEvansAFenwickNEuro Ewing ConsortiumResults of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma20193715_suppl1100710.1200/JCO.2019.37.15_suppl.11007Search in Google Scholar
McCabe MG, Kirton L, Khan M, Fenwick N, Dirksen U, Gaspar N, et al. Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). J Clin Oncol. 2020 38(15_suppl):11502.McCabeMGKirtonLKhanMFenwickNDirksenUGasparNResults of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES)20203815_suppl1150210.1200/JCO.2020.38.15_suppl.11502Search in Google Scholar
McTiernan A, Driver D, Michelagnoli MP, Kilby AM, Whelan JS. High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours. Ann Oncol. 2006 Aug;17(8):1301–1305. doi:10.1093/annonc/mdl108. Epub 2006 Jun 16. PMID: 16782749.McTiernanADriverDMichelagnoliMPKilbyAMWhelanJSHigh dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours2006Aug1781301130510.1093/annonc/mdl108Epub 2006 Jun 16. PMID: 16782749.16782749Open DOISearch in Google Scholar
Al-Faris N, Al Harbi T, Goia C, Pappo A, Doyle J, Gassas A. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatr Blood Cancer. 2007 Aug;49(2):190–195. doi:10.1002/pbc.21140. PMID: 17262797.Al-FarisNAl HarbiTGoiaCPappoADoyleJGassasADoes consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?2007Aug49219019510.1002/pbc.21140PMID: 17262797.17262797Open DOISearch in Google Scholar
Rasper M, Jabar S, Ranft A, Jürgens H, Amler S, Dirksen U. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer. 2014 Aug;61(8):1382–1386. doi:10.1002/pbc.25042. Epub 2014 Apr 11. PMID: 24729428.RasperMJabarSRanftAJürgensHAmlerSDirksenUThe value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma2014Aug6181382138610.1002/pbc.25042Epub 2014 Apr 11. PMID: 24729428.24729428Open DOISearch in Google Scholar
Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol. 2005 Jul 1;23(19):4354–4362. doi:10.1200/JCO.2005.05.105. Epub 2005 Mar 21. PMID: 15781881.BarkerLMPendergrassTWSandersJEHawkinsDSSurvival after recurrence of Ewing's sarcoma family of tumors2005Jul123194354436210.1200/JCO.2005.05.105Epub 2005 Mar 21. PMID: 15781881.15781881Open DOISearch in Google Scholar
Koscielniak E, Gross-Wieltsch U, Treuner J, Winkler P, Klingebiel T, Lang P, et al. Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J Clin Oncol. 2005 Jan 1;23(1):242–244. doi:10.1200/JCO.2005.05.940. PMID: 15625381.KoscielniakEGross-WieltschUTreunerJWinklerPKlingebielTLangPGraft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease2005Jan123124224410.1200/JCO.2005.05.940PMID: 15625381.15625381Open DOISearch in Google Scholar
Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM, et al., EBMT Solid Tumors Working Party. Transplantation of allogeneic hematopoietic stem cells: An emerging treatment modality for solid tumors. Nat Clin Pract Oncol. 2008 May;5(5):256–67. doi:10.1038/ncponc1104. Epub 2008 Apr 8. PMID: 18398414.DemirerTBarkholtLBlaiseDPedrazzoliPAgliettaMCarellaAMEBMT Solid Tumors Working PartyTransplantation of allogeneic hematopoietic stem cells: An emerging treatment modality for solid tumors2008May552566710.1038/ncponc1104Epub 2008 Apr 8. PMID: 18398414.18398414Open DOISearch in Google Scholar
Hale GA. Autologous hematopoietic stem cell transplantation for pediatric solid tumors. Expert Rev Anticancer Ther. 2005 Oct;5(5):835–846. doi:10.1586/14737140.5.5.835. PMID: 16221053.HaleGAAutologous hematopoietic stem cell transplantation for pediatric solid tumors2005Oct5583584610.1586/14737140.5.5.835PMID: 16221053.16221053Open DOISearch in Google Scholar
Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD, Egerer G. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant. 2004 Jul;34(1):37–41. doi:10.1038/sj.bmt.1704520. PMID: 15170176.KasperBLehnertTBerndLMechtersheimerGGoldschmidtHHoADEgererGHigh-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas2004Jul341374110.1038/sj.bmt.1704520PMID: 15170176.15170176Open DOISearch in Google Scholar
Baird K, Fry TJ, Steinberg SM, Bishop MR, Fowler DH, Delbrook CP, et al. Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant. 2012 May;18(5):698–707. doi:10.1016/j.bbmt.2011.08.020. Epub 2011 Sep 5. PMID: 21896345; PMCID: PMC3262116.BairdKFryTJSteinbergSMBishopMRFowlerDHDelbrookCPReduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas2012May18569870710.1016/j.bbmt.2011.08.020Epub 2011 Sep 5. PMID: 21896345; PMCID: PMC3262116.326211621896345Open DOISearch in Google Scholar
Drabko K, Raciborska A, Bilska K, Styczynski J, Ussowicz M, Choma M, et al. Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma. Bone Marrow Transplant. 2012 Dec;47(12):1530–1534. doi:10.1038/bmt.2012.78. Epub 2012 May 21. PMID: 22609883.DrabkoKRaciborskaABilskaKStyczynskiJUssowiczMChomaMConsolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma2012Dec47121530153410.1038/bmt.2012.78Epub 2012 May 21. PMID: 22609883.22609883Open DOISearch in Google Scholar
Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS, et al. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 2017 Jun 15;123(12):2206–2218. doi:10.1002/cncr.30589. Epub 2017 Mar 21. PMID: 28323337; PMCID: PMC5485018.ReedDRHayashiMWagnerLBinitieOSteppanDABrohlASTreatment pathway of bone sarcoma in children, adolescents, and young adults2017Jun15123122206221810.1002/cncr.30589Epub 2017 Mar 21. PMID: 28323337; PMCID: PMC5485018.548501828323337Open DOISearch in Google Scholar
Leemann-Zakaryan RP, Pahlich S, Sedda MJ, Quero L, Grossenbacher D, Gehring H. Dynamic subcellular localization of the Ewing sarcoma proto-oncoprotein and its association with and stabilization of microtubules. J Mol Biol. 2009 Feb 13;386(1):1–13. doi:10.1016/j.jmb.2008.12.039. Epub 2008 Dec 24. PMID: 19133275.Leemann-ZakaryanRPPahlichSSeddaMJQueroLGrossenbacherDGehringHDynamic subcellular localization of the Ewing sarcoma proto-oncoprotein and its association with and stabilization of microtubules2009Feb13386111310.1016/j.jmb.2008.12.039Epub 2008 Dec 24. PMID: 19133275.19133275Open DOISearch in Google Scholar
Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Aug;60(8):1325–1332. doi:10.1002/pbc.24517. Epub 2013 Mar 28. PMID: 23553917; PMCID: PMC4263960.KolbEAGorlickRReynoldsCPKangMHCarolHLockRInitial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program2013Aug6081325133210.1002/pbc.24517Epub 2013 Mar 28. PMID: 23553917; PMCID: PMC4263960.426396023553917Open DOISearch in Google Scholar
Wagner LM, Yin H, Eaves D, Currier M, Cripe TP. Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma. Pediatr Blood Cancer. 2014 Nov;61(11):2096–2098. doi:10.1002/pbc.25062. Epub 2014 Apr 19. PMID: 24753077.WagnerLMYinHEavesDCurrierMCripeTPPreclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma2014Nov61112096209810.1002/pbc.25062Epub 2014 Apr 19. PMID: 24753077.24753077Open DOISearch in Google Scholar
Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, et al. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer. 2012 Nov;48(16):3036–3044. doi:10.1016/j.ejca.2012.05.012. Epub 2012 Jun 29. PMID: 22749255.Le CesneACrestaSMakiRGBlayJYVerweijJPovedaAA retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas2012Nov48163036304410.1016/j.ejca.2012.05.012Epub 2012 Jun 29. PMID: 22749255.22749255Open DOISearch in Google Scholar
Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, et al. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group. Eur J Cancer. 2012 Mar;48(4):579–585. doi:10.1016/j.ejca.2011.09.027. Epub 2011 Nov 14. PMID: 22088484.BaruchelSPappoAKrailoMBakerKSWuBVillalunaDA phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group2012Mar48457958510.1016/j.ejca.2011.09.027Epub 2011 Nov 14. PMID: 22088484.22088484Open DOISearch in Google Scholar
Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, et al. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104). Int J Cancer. 2013 Nov;133(9):2024–2033. doi:10.1002/ijc.28213. Epub 2013 May 25. PMID: 23588839.RomanoMFrapolliRZangariniMBelloEPorcuLGalmariniCMComparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)2013Nov13392024203310.1002/ijc.28213Epub 2013 May 25. PMID: 23588839.23588839Open DOISearch in Google Scholar
Subbiah V, Kumar Sankhala K, Ratan R, Sanz Garcia E, Boni V, Gil T, et al. Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study. J Clin Oncol. 2018;36(15_suppl):11519.SubbiahVKumar SankhalaKRatanRSanz GarciaEBoniVGilTEfficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study20183615_suppl1151910.1200/JCO.2018.36.15_suppl.11519Search in Google Scholar
Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012 Apr 1;72(7):1608–1613. doi:10.1158/0008-5472.CAN-11-3648. Epub 2012 Jan 27. PMID: 22287547; PMCID: PMC3319786.BrennerJCFengFYHanSPatelSGoyalSVBou-MarounLMPARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma2012Apr17271608161310.1158/0008-5472.CAN-11-3648Epub 2012 Jan 27. PMID: 22287547; PMCID: PMC3319786.331978622287547Open DOISearch in Google Scholar
Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012 Mar 28;483(7391):570–575. doi:10.1038/nature11005. PMID: 22460902; PMCID: PMC3349233.GarnettMJEdelmanEJHeidornSJGreenmanCDDasturALauKWSystematic identification of genomic markers of drug sensitivity in cancer cells2012Mar28483739157057510.1038/nature11005PMID: 22460902; PMCID: PMC3349233.334923322460902Open DOISearch in Google Scholar
Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 5;14:813. doi:10.1186/1471-2407-14-813. PMID: 25374341; PMCID: PMC4230717.ChoyEButrynskiJEHarmonDCMorganJAGeorgeSWagnerAJPhase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy2014Nov51481310.1186/1471-2407-14-813PMID: 25374341; PMCID: PMC4230717.423071725374341Open DOISearch in Google Scholar
Vormoor B, Schlosser YT, Blair H, Sharma A, Wilkinson S, Newell DR, Curtin N. Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2. Oncotarget. 2017 Sep 28;8(69):113418–113430. doi:10.18632/oncotarget.21300. PMID: 29371919; PMCID: PMC5768336.VormoorBSchlosserYTBlairHSharmaAWilkinsonSNewellDRCurtinNSensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/22017Sep2886911341811343010.18632/oncotarget.21300PMID: 29371919; PMCID: PMC5768336.576833629371919Open DOISearch in Google Scholar
Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 2014 Nov 6;9(3):829–841. doi:10.1016/j.celrep.2014.09.028. Epub 2014 Oct 23. PMID: 25437539; PMCID: PMC4386669.StewartEGoshornRBradleyCGriffithsLMBenaventeCTwarogNRTargeting the DNA repair pathway in Ewing sarcoma2014Nov69382984110.1016/j.celrep.2014.09.028Epub 2014 Oct 23. PMID: 25437539; PMCID: PMC4386669.438666925437539Open DOISearch in Google Scholar
Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, et al. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2015 Feb 15;21(4):819–832. doi:10.1158/1078-0432.CCR-14-2572. Epub 2014 Dec 10. Erratum in: Clin Cancer Res. 2017 Feb 15;23 (4):1118–1119. PMID: 25500058; PMCID: PMC4587665.SmithMAReynoldsCPKangMHKolbEAGorlickRCarolHSynergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program2015Feb1521481983210.1158/1078-0432.CCR-14-2572Epub 2014 Dec 10. Erratum in: Clin Cancer Res. 2017 Feb 15;23 (4):1118–1119. PMID: 25500058; PMCID: PMC4587665.458766525500058Open DOISearch in Google Scholar
Wilcoxen KM, Brooks DG, Tiruchinapalli D, Anderson N, Donaldson R, McIver Nivens, et al. The PARP inhibitor niraparib demonstrates synergy with chemotherapy in treatment of patient derived Ewing's sarcoma tumorGraft models [abstract]. In Proceedings of the AACR-NCI-EORTC International Conference: Molecular targets and cancer therapeutics; 2013 Oct 19–23; Boston, MA: AACR; Mol Cancer Ther. 2013;12(11 Suppl):Abstract nr A258.WilcoxenKMBrooksDGTiruchinapalliDAndersonNDonaldsonRMcIverNivensThe PARP inhibitor niraparib demonstrates synergy with chemotherapy in treatment of patient derived Ewing's sarcoma tumorGraft models [abstract]. In Proceedings of the AACR-NCI-EORTC International Conference: Molecular targets and cancer therapeutics; 2013 Oct 19–23; Boston, MA: AACR20131211 SupplAbstract nr A258.10.1158/1535-7163.TARG-13-A258Search in Google Scholar
Gill SJ, Travers J, Pshenichnaya I, Kogera FA, Barthorpe S, Mironenko T, et al. Combinations of PARP inhibitors with temozolomide drive PARP1 trapping and apoptosis in Ewing's sarcoma. PLoS One. 2015 Oct 27;10(10):e0140988. doi:10.1371/journal.pone.0140988. PMID: 26505995; PMCID: PMC4624427.GillSJTraversJPshenichnayaIKogeraFABarthorpeSMironenkoTCombinations of PARP inhibitors with temozolomide drive PARP1 trapping and apoptosis in Ewing's sarcoma2015Oct271010e0140988.10.1371/journal.pone.0140988PMID: 26505995; PMCID: PMC4624427.462442726505995Open DOISearch in Google Scholar
Iniguez AB, Stolte B, Wang EJ, Conway AS, Alexe G, Dharia NV, et al. EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma. Cancer Cell. 2018 Feb 12;33(2):202–216.e6. doi:10.1016/j.ccell.2017.12.009. Epub 2018 Jan 18. PMID: 29358035; PMCID: PMC5846483.IniguezABStolteBWangEJConwayASAlexeGDhariaNVEWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma2018Feb12332202216e610.1016/j.ccell.2017.12.009Epub 2018 Jan 18. PMID: 29358035; PMCID: PMC5846483.584648329358035Open DOISearch in Google Scholar
Tang F, Choy E, Tu C, Hornicek F, Duan Z. Therapeutic applications of histone deacetylase inhibitors in sarcoma. Cancer Treat Rev. 2017 Sep;59:33–45. doi:10.1016/j.ctrv.2017.06.006. Epub 2017 Jul 6. PMID: 28732326; PMCID: PMC5581728.TangFChoyETuCHornicekFDuanZTherapeutic applications of histone deacetylase inhibitors in sarcoma2017Sep59334510.1016/j.ctrv.2017.06.006Epub 2017 Jul 6. PMID: 28732326; PMCID: PMC5581728.558172828732326Open DOISearch in Google Scholar
Sampson ER, Amin V, Schwarz EM, O’Keefe RJ, Rosier RN. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy. J Orthop Res. 2011 Apr;29(4):623–32. doi:10.1002/jor.21274. Epub 2010 Oct 18. PMID: 20957741.SampsonERAminVSchwarzEMO’KeefeRJRosierRNThe histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy2011Apr2946233210.1002/jor.21274Epub 2010 Oct 18. PMID: 20957741.20957741Open DOISearch in Google Scholar
Heinicke U, Kupka J, Fulda S. JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis. Oncotarget. 2015 Nov 10;6(35):37836–37851. doi:10.18632/oncotarget.6097. PMID: 26473375; PMCID: PMC4741969.HeinickeUKupkaJFuldaSJNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis2015Nov10635378363785110.18632/oncotarget.6097PMID: 26473375; PMCID: PMC4741969.474196926473375Open DOISearch in Google Scholar
Heinicke U, Fulda S. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA. Cancer Lett. 2014 Aug 28;351(1):50–58. doi:10.1016/j.canlet.2014.04.021. Epub 2014 May 6. PMID: 24814395.HeinickeUFuldaSChemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA2014Aug283511505810.1016/j.canlet.2014.04.021Epub 2014 May 6. PMID: 24814395.24814395Open DOISearch in Google Scholar
Sampson VB, Vetter NS, Kamara DF, Collier AB, Gresh RC, Kolb EA. Vorinostat enhances cytotoxicity of SN-38 and temozolomide in Ewing sarcoma cells and activates STAT3/AKT/MAPK pathways. PLoS One. 2015 Nov 16;10(11):e0142704. doi:10.1371/journal.pone.0142704. PMID: 26571493; PMCID: PMC4646493.SampsonVBVetterNSKamaraDFCollierABGreshRCKolbEAVorinostat enhances cytotoxicity of SN-38 and temozolomide in Ewing sarcoma cells and activates STAT3/AKT/MAPK pathways2015Nov161011e014270410.1371/journal.pone.0142704PMID: 26571493; PMCID: PMC4646493.464649326571493Open DOISearch in Google Scholar
Unland R, Clemens D, Heinicke U, Potratz JC, Hotfilder M, Fulda S, et al. Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines. Anticancer Drugs. 2015 Sep;26(8):843–851. doi:10.1097/CAD.0000000000000256. PMID: 26053276.UnlandRClemensDHeinickeUPotratzJCHotfilderMFuldaSSuberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines2015Sep26884385110.1097/CAD.0000000000000256PMID: 26053276.26053276Open DOISearch in Google Scholar
Schonn I, Hennesen J, Dartsch DC. Ku70 and Rad51 vary in their importance for the repair of doxorubicin-versus etoposide-induced DNA damage. Apoptosis. 2011 Apr;16(4):359–369. doi:10.1007/s10495-010-0564-y. PMID: 21107697.SchonnIHennesenJDartschDCKu70 and Rad51 vary in their importance for the repair of doxorubicin-versus etoposide-induced DNA damage2011Apr16435936910.1007/s10495-010-0564-yPMID: 21107697.21107697Open DOISearch in Google Scholar
Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, et al. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res. 2009 May 15;15(10):3472–83. doi:10.1158/1078-0432.CCR-08-2714. Epub 2009 May 5. Erratum in Clin Cancer Res. 2015 Apr 1;21(7):1774–1775. PMID: 19417021.LopezGLiuJRenWWeiWWangSLahatGCombining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma2009May15151034728310.1158/1078-0432.CCR-08-2714Epub 2009 May 5. Erratum in Clin Cancer Res. 2015 Apr 1;21(7):1774–1775. PMID: 19417021.19417021Open DOISearch in Google Scholar
Becker M, Graf C, Tonak M, Radsak MP, Bopp T, Bals R, et al. Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents. Oncol Lett. 2016 Aug;12(2):1257–1264. doi:10.3892/ol.2016.4784. Epub 2016 Jun 24. PMID: 27446424; PMCID: PMC4950181.BeckerMGrafCTonakMRadsakMPBoppTBalsRXenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents2016Aug1221257126410.3892/ol.2016.4784Epub 2016 Jun 24. PMID: 27446424; PMCID: PMC4950181.495018127446424Open DOISearch in Google Scholar
Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X, et al. Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemother Pharmacol. 2011 Feb;67(2):439–446. doi:10.1007/s00280-010-1344-7. Epub 2010 May 12. PMID: 20461381.YangCChoyEHornicekFJWoodKBSchwabJHLiuXHistone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells2011Feb67243944610.1007/s00280-010-1344-7Epub 2010 May 12. PMID: 20461381.20461381Open DOISearch in Google Scholar
Capobianco E, Mora A, La Sala D, Roberti A, Zaki N, et al. Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line. PLoS One. 2014 Apr 22;9(4):e95596. doi:10.1371/journal.pone.0095596. PMID: 24756038; PMCID: PMC3995708.CapobiancoEMoraALa SalaDRobertiAZakiNSeparate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line2014Apr2294e9559610.1371/journal.pone.0095596PMID: 24756038; PMCID: PMC3995708.399570824756038Open DOISearch in Google Scholar
Nakamura T, Matsumine A, Kawai A, Araki N, Goto T, Yonemoto T, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016 May 1;122(9):1408–1416. doi:10.1002/cncr.29961. Epub 2016 Mar 11. PMID: 26970174; PMCID: PMC5069581.NakamuraTMatsumineAKawaiAArakiNGotoTYonemotoTThe clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study2016May112291408141610.1002/cncr.29961Epub 2016 Mar 11. PMID: 26970174; PMCID: PMC5069581.506958126970174Open DOISearch in Google Scholar
Loganathan SN, Tang N, Fleming JT, Ma Y, Guo Y, Borinstein SC, et al. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Oncotarget. 2016 Jul 12;7(28):43504–43517. doi:10.18632/oncotarget.9762. PMID: 27259270; PMCID: PMC5190040.LoganathanSNTangNFlemingJTMaYGuoYBorinsteinSCBET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma2016Jul12728435044351710.18632/oncotarget.9762PMID: 27259270; PMCID: PMC5190040.519004027259270Open DOISearch in Google Scholar
Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, et al. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Oncotarget. 2016 Jan 12;7(2):1451–1463. doi:10.18632/oncotarget.6385. PMID: 26623725; PMCID: PMC4811472.HenselTGiorgiCSchmidtOCalzada-WackJNeffFBuchTNiggliFKTargeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma2016Jan12721451146310.18632/oncotarget.6385PMID: 26623725; PMCID: PMC4811472.481147226623725Open DOISearch in Google Scholar
Pedersen MT, Helin K. Histone demethylases in development and disease. Trends Cell Biol. 2010 Nov;20(11):662–671. doi:10.1016/j.tcb.2010.08.011. Epub 2010 Sep 20. PMID: 20863703.PedersenMTHelinKHistone demethylases in development and disease2010Nov201166267110.1016/j.tcb.2010.08.011Epub 2010 Sep 20. PMID: 20863703.20863703Open DOISearch in Google Scholar
Chen Y, Jie W, Yan W, Zhou K, Xiao Y. Lysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy. Crit Rev Eukaryot Gene Expr. 2012;22(1):53–59. doi:10.1615/critreveukargeneexpr.v22.i1.40. PMID: 22339659.ChenYJieWYanWZhouKXiaoYLysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy2012221535910.1615/critreveukargeneexpr.v22.i1.40PMID: 22339659.22339659Open DOISearch in Google Scholar
Theisen ER, Pishas KI, Saund RS, Lessnick SL. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget. 2016 Apr 5;7(14):17616–17630. doi:10.18632/oncotarget.7124. PMID: 26848860; PMCID: PMC4951237.TheisenERPishasKISaundRSLessnickSLTherapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting2016Apr5714176161763010.18632/oncotarget.7124PMID: 26848860; PMCID: PMC4951237.495123726848860Open DOISearch in Google Scholar
Spriano F, Chung EYL, Gaudio E, Tarantelli C, Cascione L, Napoli S, et al. The ETS inhibitors YK-4-279 and TK-216 are novel antilymphoma agents. Clin Cancer Res. 2019 Aug 15;25(16):5167–5176. doi:10.1158/1078-0432.CCR-18-2718. Epub 2019 Jun 10. PMID: 31182435.SprianoFChungEYLGaudioETarantelliCCascioneLNapoliSThe ETS inhibitors YK-4-279 and TK-216 are novel antilymphoma agents2019Aug1525165167517610.1158/1078-0432.CCR-18-2718Epub 2019 Jun 10. PMID: 31182435.31182435Open DOISearch in Google Scholar
Stega J, Noel MS, Vandell AG, Stega D, Del Priore G, Hoffman S. A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer. Invest New Drugs. 2020 Apr;38(2):392–401. doi:10.1007/s10637-019-00758-8. Epub 2019 Mar 30. PMID: 30929156; PMCID: PMC7066285.StegaJNoelMSVandellAGStegaDDel PrioreGHoffmanSA first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer2020Apr38239240110.1007/s10637-019-00758-8Epub 2019 Mar 30. PMID: 30929156; PMCID: PMC7066285.706628530929156Open DOISearch in Google Scholar
Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704–707. doi:10.1038/366704a0. PMID: 8259215.SerranoMHannonGJBeachDA new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK41993Dec16366645670470710.1038/366704a0PMID: 8259215.8259215Open DOISearch in Google Scholar
Kennedy AL, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F, et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget. 2015 Oct 6;6(30):30178–30193. doi:10.18632/oncotarget.4903. PMID: 26337082; PMCID: PMC4745789.KennedyALVallurupalliMChenLCromptonBCowleyGVazquezFFunctional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma2015Oct6630301783019310.18632/oncotarget.4903PMID: 26337082; PMCID: PMC4745789.474578926337082Open DOISearch in Google Scholar
Dowless M, Lowery CD, Shackleford T, Renschler M, Stephens J, Flack R, et al. Abemaciclib is active in preclinical models of Ewing sarcoma via multipronged regulation of cell cycle, DNA methylation, and interferon pathway signaling. Clin Cancer Res. 2018 Dec 1;24(23):6028–6039. doi:10.1158/1078-0432.CCR-18-1256. Epub 2018 Aug 21. PMID: 30131386; PMCID: PMC6279561.DowlessMLoweryCDShacklefordTRenschlerMStephensJFlackRAbemaciclib is active in preclinical models of Ewing sarcoma via multipronged regulation of cell cycle, DNA methylation, and interferon pathway signaling2018Dec124236028603910.1158/1078-0432.CCR-18-1256Epub 2018 Aug 21. PMID: 30131386; PMCID: PMC6279561.627956130131386Open DOISearch in Google Scholar
Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993 Apr 29;362(6423):857–860. doi:10.1038/362857a0. PMID: 8479525.OlinerJDPietenpolJAThiagalingamSGyurisJKinzlerKWVogelsteinBOncoprotein MDM2 conceals the activation domain of tumour suppressor p531993Apr29362642385786010.1038/362857a0PMID: 8479525.8479525Open DOISearch in Google Scholar
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24;119(5):591–602. doi:10.1016/j.cell.2004.11.022. PMID: 15550242.BondGLHuWBondEERobinsHLutzkerSGArvaNCA single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans2004Nov24119559160210.1016/j.cell.2004.11.022PMID: 15550242.15550242Open DOISearch in Google Scholar
Shi D, Gu W. Dual roles of MDM2 in the regulation of p53: Ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity. Genes Cancer. 2012 Mar;3(3–4):240–248. doi:10.1177/1947601912455199. PMID: 23150757; PMCID: PMC3494363.ShiDGuWDual roles of MDM2 in the regulation of p53: Ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity2012Mar33–424024810.1177/1947601912455199PMID: 23150757; PMCID: PMC3494363.349436323150757Open DOISearch in Google Scholar
Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, et al. Nutlin-3a is a potential therapeutic for Ewing sarcoma. Clin Cancer Res. 2011 Feb 1;17(3):494–504. doi:10.1158/1078-0432.CCR-10-1587. Epub 2010 Nov 23. PMID: 21098696.PishasKIAl-EjehFZinonosIKumarREvdokiouABrownMPNutlin-3a is a potential therapeutic for Ewing sarcoma2011Feb117349450410.1158/1078-0432.CCR-10-1587Epub 2010 Nov 23. PMID: 21098696.21098696Open DOISearch in Google Scholar
Wang H, Ma X, Ren S, Buolamwini JK, Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther. 2011 Jan;10(1):69–79. doi:10.1158/1535-7163.MCT-10-0581. Epub 2010 Nov 12. PMID: 21075910; PMCID: PMC3058295.WangHMaXRenSBuolamwiniJKYanCA small-molecule inhibitor of MDMX activates p53 and induces apoptosis2011Jan101697910.1158/1535-7163.MCT-10-0581Epub 2010 Nov 12. PMID: 21075910; PMCID: PMC3058295.305829521075910Open DOISearch in Google Scholar
Depping R, von Fallois M, Landesman Y, Kosyna FK. The nuclear export inhibitor selinexor inhibits hypoxia signaling pathways and 3D spheroid growth of cancer cells. Onco Targets Ther. 2019 Oct 11;12:8387–8399. doi:10.2147/OTT.S213208. PMID: 31632086; PMCID: PMC6793465.DeppingRvon FalloisMLandesmanYKosynaFKThe nuclear export inhibitor selinexor inhibits hypoxia signaling pathways and 3D spheroid growth of cancer cells2019Oct11128387839910.2147/OTT.S213208PMID: 31632086; PMCID: PMC6793465.679346531632086Open DOISearch in Google Scholar
Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, et al. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol. 2016 Sep 10;34(26):3166–3174. doi:10.1200/JCO.2016.67.6346. Epub 2016 Jul 25. Erratum in J Clin Oncol. 2017 Mar;35(7):812. PMID: 27458288; PMCID: PMC5321073.GounderMMZerATapWDSalahSDicksonMAGuptaAAPhase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma2016Sep1034263166317410.1200/JCO.2016.67.6346Epub 2016 Jul 25. Erratum in J Clin Oncol. 2017 Mar;35(7):812. PMID: 27458288; PMCID: PMC5321073.532107327458288Open DOISearch in Google Scholar
Taylor-Kashton C, Lichtensztejn D, Baloglu E, Senapedis W, Shacham S, Kauffman MG, et al. XPO1 inhibition preferentially disrupts the 3D nuclear organization of telomeres in tumor cells. J Cell Physiol. 2016 Dec;231(12):2711–2719. doi:10.1002/jcp.25378. Epub 2016 Apr 8. PMID: 26991404; PMCID: PMC5111786.Taylor-KashtonCLichtensztejnDBalogluESenapedisWShachamSKauffmanMGXPO1 inhibition preferentially disrupts the 3D nuclear organization of telomeres in tumor cells2016Dec231122711271910.1002/jcp.25378Epub 2016 Apr 8. PMID: 26991404; PMCID: PMC5111786.511178626991404Open DOISearch in Google Scholar
Nakayama R, Zhang YX, Czaplinski JT, Anatone AJ, Sicinska ET, Fletcher JA, et al. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. 2016 Mar 29;7(13):16581–16592. doi:10.18632/oncotarget.7667. PMID: 26918731; PMCID: PMC4941336.NakayamaRZhangYXCzaplinskiJTAnatoneAJSicinskaETFletcherJAPreclinical activity of selinexor, an inhibitor of XPO1, in sarcoma2016Mar29713165811659210.18632/oncotarget.7667PMID: 26918731; PMCID: PMC4941336.494133626918731Open DOISearch in Google Scholar
Nair JS, Musi E, Schwartz GK. Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IκB and downregulation of survivin. Clin Cancer Res. 2017 Aug 1;23(15):4301–4311. doi:10.1158/1078-0432.CCR-16-2632. Epub 2017 Mar 17. PMID: 28314790.NairJSMusiESchwartzGKSelinexor (KPT-330) induces tumor suppression through nuclear sequestration of IκB and downregulation of survivin2017Aug123154301431110.1158/1078-0432.CCR-16-2632Epub 2017 Mar 17. PMID: 28314790.28314790Open DOISearch in Google Scholar
Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, et al. Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. 2016 Nov 29;7(48):78883–78895. doi:10.18632/oncotarget.12428. PMID: 27713151; PMCID: PMC5346685.KashyapTArguetaCAboukameelAUngerTJKlebanovBMohammadRMSelinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death2016Nov29748788837889510.18632/oncotarget.12428PMID: 27713151; PMCID: PMC5346685.534668527713151Open DOISearch in Google Scholar
Ahmed AA, Sherman AK, Pawel BR. Expression of therapeutic targets in Ewing sarcoma family tumors. Hum Pathol. 2012 Jul;43(7):1077–1083. doi:10.1016/j.humpath.2011.09.001. Epub 2011 Dec 21. PMID: 22196127.AhmedAAShermanAKPawelBRExpression of therapeutic targets in Ewing sarcoma family tumors2012Jul4371077108310.1016/j.humpath.2011.09.001Epub 2011 Dec 21. PMID: 22196127.22196127Open DOISearch in Google Scholar
Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008 Jan 20;26(3):361–67. doi:10.1200/JCO.2007.12.0345. PMID: 18202410.MitaMMMitaACChuQSRowinskyEKFetterlyGJGoldstonMPhase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies2008Jan202633616710.1200/JCO.2007.12.0345PMID: 18202410.18202410Open DOISearch in Google Scholar
Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, et al. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A Children's Oncology Group Study. Pediatr Blood Cancer. 2014 May;61(5):833–839. doi:10.1002/pbc.24874. Epub 2013 Nov 19. PMID: 24249672; PMCID: PMC4196713.BagatellRNorrisRIngleAMAhernCVossSFoxEPhase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A Children's Oncology Group Study2014May61583383910.1002/pbc.24874Epub 2013 Nov 19. PMID: 24249672; PMCID: PMC4196713.419671324249672Open DOISearch in Google Scholar
Trucco MM, Meyer CF, Thornton KA, Shah P, Chen AR, Wilky BA, et al. A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. Clin Sarcoma Res. 2018 Nov 5;8:21. doi:10.1186/s13569-018-0107-9. PMID: 30410720; PMCID: PMC6217787.TruccoMMMeyerCFThorntonKAShahPChenARWilkyBAA phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas2018Nov582110.1186/s13569-018-0107-9PMID: 30410720; PMCID: PMC6217787.621778730410720Open DOISearch in Google Scholar
Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004 Aug;24(16):7275–7283. doi:10.1128/MCB.24.16.7275-7283.2004. PMID: 15282325; PMCID: PMC479730.PrieurATirodeFCohenPDelattreOEWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 32004Aug24167275728310.1128/MCB.24.16.7275-7283.2004PMID: 15282325; PMCID: PMC479730.47973015282325Open DOISearch in Google Scholar
Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target. Cancer Res. 1996 Oct 15;56(20):4570–4574. PMID: 8840962.ScotlandiKBeniniSSartiMSerraMLolliniPLMauriciDInsulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target1996Oct15562045704574PMID: 8840962.Search in Google Scholar
Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH. Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Ther. 2010 May;9(5):1396–1407. doi:10.1158/1535-7163.MCT-09-0604. Epub 2010 Apr 27. PMID: 20423994.KangHGJenabiJMLiuXFReynoldsCPTricheTJSorensenPHInhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells2010May951396140710.1158/1535-7163.MCT-09-0604Epub 2010 Apr 27. PMID: 20423994.20423994Open DOISearch in Google Scholar
Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res. 2007 Feb 15;13(4):1322–1330. doi:10.1158/1078-0432.CCR-06-1518. PMID: 17317844ManaraMCLanduzziLNanniPNicolettiGZambelliDLolliniPLPreclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma2007Feb151341322133010.1158/1078-0432.CCR-06-1518PMID: 1731784417317844Open DOISearch in Google Scholar
Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 1998 Sep 15;58(18):4127–4131. PMID: 9751624.ScotlandiKBeniniSNanniPLolliniPLNicolettiGLanduzziLBlockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice1998Sep15581841274131PMID: 9751624.Search in Google Scholar
Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009 Dec 1;27(34):5800–5807. doi:10.1200/JCO.2009.23.6745. Epub 2009 Sep 28. PMID: 19786654.TolcherAWSarantopoulosJPatnaikAPapadopoulosKLinCCRodonJPhase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 12009Dec127345800580710.1200/JCO.2009.23.6745Epub 2009 Sep 28. PMID: 19786654.19786654Open DOISearch in Google Scholar
Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 2012 May 20;30(15):1849–1856. doi:10.1200/JCO.2011.37.2359. Epub 2012 Apr 16. PMID: 22508822.TapWDDemetriGBarnettePDesaiJKavanPTozerRPhase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors2012May2030151849185610.1200/JCO.2011.37.2359Epub 2012 Apr 16. PMID: 22508822.22508822Open DOISearch in Google Scholar
Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines. 2017 Jun 21;5(2):34. doi:10.3390/biomedicines5020034. PMID: 28635679; PMCID: PMC5489820.RajabiMMousaSAThe role of angiogenesis in cancer treatment2017Jun21523410.3390/biomedicines5020034PMID: 28635679; PMCID: PMC5489820.548982028635679Open DOISearch in Google Scholar
DuBois SG, Marina N, Glade-Bender J. Angiogenesis and vascular targeting in Ewing sarcoma: A review of preclinical and clinical data. Cancer. 2010 Feb 1;116(3):749–757. doi:10.1002/cncr.24844. PMID: 20029966; PMCID: PMC2815027.DuBoisSGMarinaNGlade-BenderJAngiogenesis and vascular targeting in Ewing sarcoma: A review of preclinical and clinical data2010Feb1116374975710.1002/cncr.24844PMID: 20029966; PMCID: PMC2815027.281502720029966Open DOISearch in Google Scholar
Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, et al. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res. 2007 Aug 15;13(16):4867–4873. doi:10.1158/1078-0432.CCR-07-0133. PMID: 17699866.ZhouZBolontradeMFReddyKDuanXGuanHYuLSuppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy2007Aug1513164867487310.1158/1078-0432.CCR-07-0133PMID: 17699866.17699866Open DOISearch in Google Scholar
Reddy K, Zhou Z, Schadler K, Jia SF, Kleinerman ES. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. Mol Cancer Res. 2008 Jun;6(6):929–936. doi:10.1158/1541-7786.MCR-07-2189. PMID: 18567797; PMCID: PMC2441901.ReddyKZhouZSchadlerKJiaSFKleinermanESBone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels2008Jun6692993610.1158/1541-7786.MCR-07-2189PMID: 18567797; PMCID: PMC2441901.244190118567797Open DOISearch in Google Scholar
Potikyan G, Savene RO, Gaulden JM, France KA, Zhou Z, Kleinerman ES, et al. EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. Cancer Res. 2007 Jul 15;67(14):6675–6684. doi:10.1158/0008-5472.CAN-06-4140. PMID: 17638877.PotikyanGSaveneROGauldenJMFranceKAZhouZKleinermanESEWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins2007Jul1567146675668410.1158/0008-5472.CAN-06-4140PMID: 17638877.17638877Open DOISearch in Google Scholar
Bukowski RM, Yasothan U, Kirkpatrick P, Pazopanib. Nat Rev Drug Discov. 2010 Jan;9(1):17–18. doi:10.1038/nrd3073. PMID: 20043026.BukowskiRMYasothanUKirkpatrickPPazopanib2010Jan91171810.1038/nrd3073PMID: 20043026.20043026Open DOISearch in Google Scholar
van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al., EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879–1886. doi:10.1016/S0140-6736(12)60651-5. Epub 2012 May 16. PMID: 22595799.van der GraafWTBlayJYChawlaSPKimDWBui-NguyenBCasaliPGEORTC Soft Tissue and Bone Sarcoma GroupPALETTE study groupPazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial2012May1937998291879188610.1016/S0140-6736(12)60651-5Epub 2012 May 16. PMID: 22595799.22595799Open DOISearch in Google Scholar
Alcindor T. Response of refractory Ewing sarcoma to pazopanib. Acta Oncol. 2015 Jul;54(7):1063–1064. doi:10.3109/0284186X.2014.971938. Epub 2014 Oct 27. PMID: 25345493.AlcindorTResponse of refractory Ewing sarcoma to pazopanib2015Jul5471063106410.3109/0284186X.2014.971938Epub 2014 Oct 27. PMID: 25345493.25345493Open DOISearch in Google Scholar
Attia S, Okuno SH, Robinson SI, Webber NP, Indelicato DJ, Jones RL, et al. Clinical activity of pazopanib in metastatic extraosseous Ewing sarcoma. Rare Tumors. 2015 May 21;7(2):5992. doi:10.4081/rt.2015.5992. PMID: 26266019; PMCID: PMC4508650.AttiaSOkunoSHRobinsonSIWebberNPIndelicatoDJJonesRLClinical activity of pazopanib in metastatic extraosseous Ewing sarcoma2015May2172599210.4081/rt.2015.5992PMID: 26266019; PMCID: PMC4508650.450865026266019Open DOISearch in Google Scholar
Yamamoto Y, Nozawa M, Shimizu N, Minami T, Yoshimura K, Uemura H. Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum. Int J Urol. 2014 Nov;21(11):1183–1184. doi:10.1111/iju.12546. Epub 2014 Jul 8. PMID: 25040171.YamamotoYNozawaMShimizuNMinamiTYoshimuraKUemuraHPazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum2014Nov21111183118410.1111/iju.12546Epub 2014 Jul 8. PMID: 25040171.25040171Open DOISearch in Google Scholar
Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, et al. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017 Nov 21;7(1):15963. doi:10.1038/s41598-017-13114-8. PMID: 29162825; PMCID: PMC5698336.DemblaVGroisbergRHessKFuSWhelerJHongDSOutcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors2017Nov21711596310.1038/s41598-017-13114-8PMID: 29162825; PMCID: PMC5698336.569833629162825Open DOISearch in Google Scholar
Keir ST, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012 Sep;59(3):586–588. doi:10.1002/pbc.24016. Epub 2011 Dec 20. PMID: 22190407; PMCID: PMC4245051.KeirSTMortonCLWuJKurmashevaRTHoughtonPJSmithMAInitial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program2012Sep59358658810.1002/pbc.24016Epub 2011 Dec 20. PMID: 22190407; PMCID: PMC4245051.424505122190407Open DOISearch in Google Scholar
Smith M, Kang M, Reynolds P, Gorlick R, Kolb A, Maris J, et al. Abstract LB-353: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib. Cancer Res. 2013 Apr 15; 73(8 Suppl.):LB-353. doi:10.1158/1538-7445.AM2013-LB-353.SmithMKangMReynoldsPGorlickRKolbAMarisJAbstract LB-353: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib2013Apr15738 Suppl.LB-35310.1158/1538-7445.AM2013-LB-353Open DOISearch in Google Scholar
Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020 Mar;21(3):446–455. doi:10.1016/S1470-2045(19)30825-3. Epub 2020 Feb 17. PMID: 32078813.ItalianoAMirOMathoulin-PelissierSPenelNPiperno-NeumannSBompasECabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): A multicentre, single-arm, phase 2 trial2020Mar21344645510.1016/S1470-2045(19)30825-3Epub 2020 Feb 17. PMID: 32078813.876361632078813Open DOISearch in Google Scholar
Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019 Jun 1;37(16):1424–1431. doi:10.1200/JCO.18.02374. Epub 2019 Apr 23. PMID: 31013172.DavisLEBolejackVRyanCWGanjooKNLoggersETChawlaSRandomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma2019Jun137161424143110.1200/JCO.18.02374Epub 2019 Apr 23. PMID: 31013172.779944331013172Open DOISearch in Google Scholar
Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, et al., French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: A non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019 Jan;20(1):120–133. doi:10.1016/S1470-2045(18)30742-3. Epub 2018 Nov 23. PMID: 30477937.DuffaudFMirOBoudou-RouquettePPiperno-NeumannSPenelNBompasEFrench Sarcoma GroupEfficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: A non-comparative, randomised, double-blind, placebo-controlled, phase 2 study2019Jan20112013310.1016/S1470-2045(18)30742-3Epub 2018 Nov 23. PMID: 30477937.30477937Open DOISearch in Google Scholar
Attia A, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing DA, et al. A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. J Clin Oncol. 2017; 35(15_suppl):11005.AttiaABolejackVGanjooKNGeorgeSAgulnikMRushingDAA phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results20173515_suppl1100510.1200/JCO.2017.35.15_suppl.11005Search in Google Scholar
Wang HY, Chu JF, Zhang P, Wang JQ, Yan Z, Yao SN, et al. Safety and efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in Chinese patients with advanced/metastatic soft tissue sarcoma. Onco Targets Ther. 2020 Feb 19;13:1561–1568. doi:10.2147/OTT.S235349. PMID: 32110053; PMCID: PMC7038775.WangHYChuJFZhangPWangJQYanZYaoSNSafety and efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in Chinese patients with advanced/metastatic soft tissue sarcoma2020Feb19131561156810.2147/OTT.S235349PMID: 32110053; PMCID: PMC7038775.703877532110053Open DOISearch in Google Scholar
Xu J, Xie L, Guo W, Tang X, Yang R, Yan T, et al. Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517). J Clin Oncol. 2019; 37(15_suppl):11012.XuJXieLGuoWTangXYangRYanTAnlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517)20193715_suppl1101210.1200/JCO.2019.37.15_suppl.11012Search in Google Scholar
Das SK, Menezes ME, Bhatia S, Wang XY, Emdad L, Sarkar D, Fisher PB. Gene therapies for cancer: Strategies, challenges and successes. J Cell Physiol. 2015 Feb;230(2):259–271. doi:10.1002/jcp.24791. PMID: 25196387; PMCID: PMC4363073.DasSKMenezesMEBhatiaSWangXYEmdadLSarkarDFisherPBGene therapies for cancer: Strategies, challenges and successes2015Feb230225927110.1002/jcp.24791PMID: 25196387; PMCID: PMC4363073.436307325196387Open DOISearch in Google Scholar
Rao DD, Jay C, Wang Z, Luo X, Kumar P, Eysenbach H, et al. Preclinical justification of pbi-shRNA EWS/FLI1 lipoplex (LPX) treatment for Ewing's sarcoma. Mol Ther. 2016 Aug;24(8):1412–1422. doi:10.1038/mt.2016.93. Epub 2016 May 11. PMID: 27166877; PMCID: PMC5023384.RaoDDJayCWangZLuoXKumarPEysenbachHPreclinical justification of pbi-shRNA EWS/FLI1 lipoplex (LPX) treatment for Ewing's sarcoma2016Aug2481412142210.1038/mt.2016.93Epub 2016 May 11. PMID: 27166877; PMCID: PMC5023384.502338427166877Open DOISearch in Google Scholar
Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014 Jul 10;10(7):e1004475. doi:10.1371/journal.pgen.1004475. Erratum in PLoS Genet. 2014 Aug;10(8):e1004629. PMID: 25010205; PMCID: PMC4091782.BrohlASSolomonDAChangWWangJSongYSindiriSThe genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation2014Jul10107e100447510.1371/journal.pgen.1004475Erratum in PLoS Genet. 2014 Aug;10(8):e1004629. PMID: 25010205; PMCID: PMC4091782.409178225010205Open DOISearch in Google Scholar
Liu J, Zheng X, Pang X, Li L, Wang J, Yang C, Du G. Ganglioside GD3 synthase (GD3S), a novel cancer drug target. Acta Pharm Sin B. 2018 Sep;8(5):713–720. doi:10.1016/j.apsb.2018.07.009. Epub 2018 Jul 25. PMID: 30245960; PMCID: PMC6147802.LiuJZhengXPangXLiLWangJYangCDuGGanglioside GD3 synthase (GD3S), a novel cancer drug target2018Sep8571372010.1016/j.apsb.2018.07.009Epub 2018 Jul 25. PMID: 30245960; PMCID: PMC6147802.614780230245960Open DOISearch in Google Scholar
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020 Jan 1;38(1):1–10. doi:10.1200/JCO.19.02105. Epub 2019 Nov 4. PMID: 31682550.MarabelleALeDTAsciertoPADi GiacomoAMDe Jesus-AcostaADelordJPEfficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study2020Jan138111010.1200/JCO.19.02105Epub 2019 Nov 4. PMID: 31682550.818406031682550Open DOISearch in Google Scholar
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493–1501. doi:10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Erratum in Lancet Oncol. 2017 Dec;18(12):e711. Erratum in Lancet Oncol. 2018 Jan;19(1):e8. PMID: 28988646.TawbiHABurgessMBolejackVVan TineBASchuetzeSMHuJPembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial2017Nov18111493150110.1016/S1470-2045(17)30624-1Epub 2017 Oct 4. Erratum in Lancet Oncol. 2017 Dec;18(12):e711. Erratum in Lancet Oncol. 2018 Jan;19(1):e8. PMID: 28988646.793902928988646Open DOISearch in Google Scholar
Raj S, Bui M, Gonzales R, Letson D, Antonia SJ. Impact of PDL1 expression on clinical outcomes in subtypes of sarcoma. Ann Oncol. 2014;25:iv494–iv510.RajSBuiMGonzalesRLetsonDAntoniaSJImpact of PDL1 expression on clinical outcomes in subtypes of sarcoma201425iv494iv51010.1093/annonc/mdu354.10Search in Google Scholar
Machado I, López-Guerrero JA, Scotlandi K, Picci P, Llombart-Bosch A. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). Virchows Arch. 2018 May;472(5):815–824. doi:10.1007/s00428-018-2316-2. Epub 2018 Feb 14. PMID: 29445891.MachadoILópez-GuerreroJAScotlandiKPicciPLlombart-BoschAImmunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT)2018May472581582410.1007/s00428-018-2316-2Epub 2018 Feb 14. PMID: 29445891.29445891Open DOISearch in Google Scholar
Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014 Nov;4(11):1326–1341. doi:10.1158/2159-8290.CD-13-1037. Epub 2014 Sep 3. PMID: 25186949.CromptonBDStewartCTaylor-WeinerAAlexeGKurekKCCalicchioMLThe genomic landscape of pediatric Ewing sarcoma2014Nov4111326134110.1158/2159-8290.CD-13-1037Epub 2014 Sep 3. PMID: 25186949.25186949Open DOISearch in Google Scholar
Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, et al., St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project and the International Cancer Genome Consortium. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 2014 Nov;4(11):1342–1353. doi:10.1158/2159-8290.CD-14-0622. Epub 2014 Sep 15. PMID: 25223734; PMCID: PMC4264969.TirodeFSurdezDMaXParkerMLe DeleyMCBahramiASt. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project and the International Cancer Genome Consortium. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations2014Nov4111342135310.1158/2159-8290.CD-14-0622Epub 2014 Sep 15. PMID: 25223734; PMCID: PMC4264969.426496925223734Open DOISearch in Google Scholar
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546–1558. doi:10.1126/science.1235122. PMID: 23539594; PMCID: PMC3749880.VogelsteinBPapadopoulosNVelculescuVEZhouSDiazLAJrKinzlerKWCancer genome landscapes2013Mar2933961271546155810.1126/science.1235122PMID: 23539594; PMCID: PMC3749880.374988023539594Open DOISearch in Google Scholar
Davis KL, Fox E, Reid JM, Liu X, Minard CG, Weigel B, Mackall, C. ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—A COG study. J Clin Oncol. 2017 35(15_suppl):10526.DavisKLFoxEReidJMLiuXMinardCGWeigelBMackallCADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—A COG study20173515_suppl1052610.1200/JCO.2017.35.15_suppl.10526Search in Google Scholar
D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018 Mar;19(3):416–426. doi:10.1016/S1470-2045(18)30006-8. Epub 2018 Jan 19. PMID: 29370992; PMCID: PMC6126546.D’AngeloSPMahoneyMRVan TineBAAtkinsJMilhemMMJahagirdarBNNivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomised, phase 2 trials2018Mar19341642610.1016/S1470-2045(18)30006-8Epub 2018 Jan 19. PMID: 29370992; PMCID: PMC6126546.612654629370992Open DOISearch in Google Scholar
Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G, et al. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest. 2010 Mar;120(3):668–680. doi:10.1172/JCI36667. Epub 2010 Feb 8. PMID: 20197622; PMCID: PMC2827943.RocchiAManaraMCSciandraMZambelliDNardiFNicolettiGCD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis2010Mar120366868010.1172/JCI36667Epub 2010 Feb 8. PMID: 20197622; PMCID: PMC2827943.282794320197622Open DOISearch in Google Scholar
O’Neill AF, Dearling JL, Wang Y, Tupper T, Sun Y, Aster JC, et al. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody. Clin Cancer Res. 2014 Feb 1;20(3):678–687. doi:10.1158/1078-0432.CCR-13-1660. Epub 2013 Nov 11. PMID: 24218512; PMCID: PMC3946397.O’NeillAFDearlingJLWangYTupperTSunYAsterJCTargeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody2014Feb120367868710.1158/1078-0432.CCR-13-1660Epub 2013 Nov 11. PMID: 24218512; PMCID: PMC3946397.394639724218512Open DOISearch in Google Scholar
Dobrenkov K, Ostrovnaya I, Gu J, Cheung IY, Cheung NK. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer. 2016 Oct;63(10):1780–1785. doi:10.1002/pbc.26097. Epub 2016 Jun 15. PMID: 27304202; PMCID: PMC5215083.DobrenkovKOstrovnayaIGuJCheungIYCheungNKOncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults2016Oct63101780178510.1002/pbc.26097Epub 2016 Jun 15. PMID: 27304202; PMCID: PMC5215083.521508327304202Open DOISearch in Google Scholar
Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, et al. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer. 2012 Mar 13;106(6):1123–1133. doi:10.1038/bjc.2012.57. Epub 2012 Feb 28. PMID: 22374462; PMCID: PMC3304425.KailayangiriSAltvaterBMeltzerJPschererSLueckeADierkesCThe ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting2012Mar1310661123113310.1038/bjc.2012.57Epub 2012 Feb 28. PMID: 22374462; PMCID: PMC3304425.330442522374462Open DOISearch in Google Scholar
Fisher JP, Flutter B, Wesemann F, Frosch J, Rossig C, Gustafsson K, Anderson J. Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells. Oncoimmunology. 2015 Apr 27;5(1):e1025194. doi:10.1080/2162402X.2015.1025194. PMID: 26942051; PMCID: PMC4760299.FisherJPFlutterBWesemannFFroschJRossigCGustafssonKAndersonJEffective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells2015Apr2751e102519410.1080/2162402X.2015.1025194PMID: 26942051; PMCID: PMC4760299.476029926942051Open DOISearch in Google Scholar
Lipinski M, Hirsch MR, Deagostini-Bazin H, Yamada O, Tursz T, Goridis C. Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines. Int J Cancer. 1987 Jul 15;40(1):81–86. doi:10.1002/ijc.2910400115. PMID: 3036723.LipinskiMHirschMRDeagostini-BazinHYamadaOTurszTGoridisCCharacterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines1987Jul15401818610.1002/ijc.2910400115PMID: 3036723.3036723Open DOISearch in Google Scholar
Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, et al. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer. 2012 Mar 13;106(6):1123–1133. doi:10.1038/bjc.2012.57. Epub 2012 Feb 28. PMID: 22374462; PMCID: PMC3304425.KailayangiriSAltvaterBMeltzerJPschererSLueckeADierkesCThe ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting2012Mar1310661123113310.1038/bjc.2012.57Epub 2012 Feb 28. PMID: 22374462; PMCID: PMC3304425.Open DOISearch in Google Scholar
Ghisoli M, Barve M, Mennel R, Lenarsky C, Horvath S, Wallraven G, et al. Three-year follow up of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (Vigil) in metastatic advanced Ewing's sarcoma. Mol Ther. 2016 Aug;24(8):1478–1483. doi:10.1038/mt.2016.86. Epub 2016 Apr 25. PMID: 27109631; PMCID: PMC5023386.GhisoliMBarveMMennelRLenarskyCHorvathSWallravenGThree-year follow up of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (Vigil) in metastatic advanced Ewing's sarcoma2016Aug2481478148310.1038/mt.2016.86Epub 2016 Apr 25. PMID: 27109631; PMCID: PMC5023386.502338627109631Open DOISearch in Google Scholar